People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bellerophon Therapeutics, Inc. | — | Pharmaceuticals | Series B | $25.0M | $796.9M | 2017 |
Amy Edmonds at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Amy Edmonds on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ADAM WEINSTEIN | 1 | 11 |
| ANDRE MOURA | 1 | 6 |
| Jonathan M Peacock | 1 | 4 |
| Daniel Tasse | 1 | 4 |
| Parag Shah | 1 | 4 |
| Andre V. Moura | 1 | 3 |
| JONATHAN PEACOCK | 1 | 2 |
| Scott P. Bruder | 1 | 1 |
| Peter B. Fernandes | 1 | 1 |
| Parag A. Shah | 1 | 1 |
| Daniel V. Tasse | 1 | 1 |
| Naseem P. Amin | 1 | 1 |
| Megan A. Schoeps | 1 | 1 |
| Fabian Tenenbaum | 1 | 1 |
| Naseem Amin | 1 | 1 |
| Jens Luehring | 1 | 1 |
| Mary Ann Cloyd | 1 | 1 |
| Martin Dekker | 1 | 1 |
| Peter Fernandes | 1 | 1 |
| Scott Bruder | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.